Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as Therapy
- PMID: 37375736
- PMCID: PMC10303627
- DOI: 10.3390/ph16060788
Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as Therapy
Abstract
Even before behavioral disturbances, neuroleptics, amphetamine, and domperidone application rapidly emerged severe occlusion/occlusion-like syndrome, shared innate vascular and multiorgan failure in rats, comparable to occlusion/occlusion-like syndrome described with vessel(s) occlusion or similar noxious procedures application. As therapy, i.e., activation of the collateral pathways, "bypassing key" (activated azygos vein pathway, direct blood flow delivery), the stable gastric pentadecapeptide BPC 157 is a novel solution. Recently, BPC 157 therapy particularly counteracted neuroleptic- or L-NAME-induced catalepsy, lithium intoxication, and schizophrenia positive and negative symptoms (amphetamine/methamphetamine/apomorphine/ketamine). In rats with complete calvariectomy, medication (BPC 157 10 µg/kg, 10 ng/kg ip or ig) was given 5 min after distinctive dopamine agents (mg/kg ip) (haloperidol (5), fluphenazine (5), clozapine (10), risperidone (5), olanzapine (10), quetiapine (10), or aripiprazole (10), domperidone (25), amphetamine (10), and combined amphetamine and haloperidol) and assessed at 15 min thereafter. All neuroleptic-, domperidone-, and amphetamine-induced comparable vascular and multiorgan failure severe syndrome was alleviated with BPC 157 therapy as before major vessel(s) occlusion or other similar noxious procedures. Specifically, all severe lesions in the brain (i.e., immediate swelling, hemorrhage), heart (i.e., congestion, arrhythmias), and lung (i.e., congestion, hemorrhage), as well as congestion in the liver, kidney, and gastrointestinal (stomach) tract, were resolved. Intracranial (superior sagittal sinus), portal, and caval hypertension and aortal hypotension were attenuated or eliminated. BPC 157 therapy almost annihilated arterial and venous thrombosis, peripherally and centrally. Thus, rapidly acting Virchow triad circumstances that occur as dopamine central/peripheral antagonists and agonist essential class-points, fully reversed by BPC 157 therapy, might be overwhelming for both neuroleptics and amphetamine.
Keywords: amphetamine; domperidone; neuroleptics; occlusion/occlusion-like syndromes; pentadecapeptide BPC 157; rats; vascular failure.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


















Similar articles
-
Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effect.World J Gastroenterol. 2023 Jul 21;29(27):4289-4316. doi: 10.3748/wjg.v29.i27.4289. World J Gastroenterol. 2023. PMID: 37545637 Free PMC article.
-
Pentadecapeptide BPC 157 as Therapy for Inferior Caval Vein Embolization: Recovery of Sodium Laurate-Post-Embolization Syndrome in Rats.Pharmaceuticals (Basel). 2023 Oct 23;16(10):1507. doi: 10.3390/ph16101507. Pharmaceuticals (Basel). 2023. PMID: 37895979 Free PMC article.
-
Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.Pharmaceuticals (Basel). 2023 Nov 2;16(11):1554. doi: 10.3390/ph16111554. Pharmaceuticals (Basel). 2023. PMID: 38004420 Free PMC article.
-
Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function.Pharmaceuticals (Basel). 2023 Apr 30;16(5):676. doi: 10.3390/ph16050676. Pharmaceuticals (Basel). 2023. PMID: 37242459 Free PMC article. Review.
-
New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.Inflammopharmacology. 2024 Oct;32(5):3119-3161. doi: 10.1007/s10787-024-01499-8. Epub 2024 Jul 9. Inflammopharmacology. 2024. PMID: 38980576 Review.
Cited by
-
Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution.Pharmaceuticals (Basel). 2025 Jun 10;18(6):866. doi: 10.3390/ph18060866. Pharmaceuticals (Basel). 2025. PMID: 40573261 Free PMC article. Review.
-
From Selye's and Szabo's Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities.Pharmaceuticals (Basel). 2023 Dec 7;16(12):1699. doi: 10.3390/ph16121699. Pharmaceuticals (Basel). 2023. PMID: 38139825 Free PMC article. Review.
-
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review.Pharmaceuticals (Basel). 2024 Aug 17;17(8):1081. doi: 10.3390/ph17081081. Pharmaceuticals (Basel). 2024. PMID: 39204186 Free PMC article. Review.
-
Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy.Pharmaceuticals (Basel). 2023 Jul 7;16(7):977. doi: 10.3390/ph16070977. Pharmaceuticals (Basel). 2023. PMID: 37513889 Free PMC article.
-
The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.Pharmaceuticals (Basel). 2024 Apr 3;17(4):461. doi: 10.3390/ph17040461. Pharmaceuticals (Basel). 2024. PMID: 38675421 Free PMC article. Review.
References
-
- Sikiric P., Gojkovic S., Knezevic M., Tepes M., Strbe S., Vukojevic J., Duzel A., Kralj T., Krezic I., Zizek H., et al. Stable gastric pentadecapeptide BPC 157: Prompt particular activation of the collateral pathways. Curr. Med. Chem. 2023;30:1568–1573. doi: 10.2174/0929867329666221005111553. - DOI - PubMed
-
- Sikiric P., Skrtic A., Gojkovic S., Krezic I., Zizek H., Lovric E., Sikiric S., Knezevic M., Strbe S., Milavic M., et al. Gastric pentadecapeptide BPC 157 in cytoprotection to resolve major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J. Gastroenterol. 2022;28:23–46. doi: 10.3748/wjg.v28.i1.23. - DOI - PMC - PubMed
-
- Sikiric P., Udovicic M., Barisic I., Balenovic D., Zivanovic Posilovic G., Strinic D., Uzun S., Sikiric S., Krezic I., Zizek H., et al. Stable gastric pentadecapeptide BPC 157 as useful cytoprotective peptide therapy in the hearth disturbances, myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, and thrombosis presentation. Biomedicines. 2022;10:2696. doi: 10.3390/biomedicines10112696. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials